Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 Junho 2023 - 5:17PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2023
Commission file number: 001-35223
_______________________
(Translation of registrant’s name into English)
_______________________
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
_______________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
The Registrant announces that it will hold an Annual Meeting of Shareholders on August 7, 2023, at 3:00 p.m. (Israel time) at the Registrant’s office,
Modi’in Technology Park, 2 HaMa’ayan Street, Modi’in 7177871, Israel. Attached hereto as
Exhibit 1,
Exhibit 2 and
Exhibit 3, are,
respectively, the Notice of Annual General Meeting and Proxy Statement, Proxy Card and Voting Instruction Card for holders of American Depositary Shares.
This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant
under the Securities Act of 1933.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
BioLineRx Ltd.
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
Philip A. Serlin
|
|
|
|
Chief Executive Officer
|
|
Dated: June 23, 2023
BioLineRx (NASDAQ:BLRX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
BioLineRx (NASDAQ:BLRX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024